Livzon Pharmaceutical concludes share repurchase, novel psoriasis drug advances

Livzon Pharmaceutical Group has completed its A-share repurchase program, acquiring 16,193,259 shares, representing 1.79% of its total share capital. The repurchase, executed between December 25, 2024, and November 7, 2025, involved a total capital outlay of RMB 600,217,787.75, with prices ranging from RMB 33.21 to RMB 41.99 per share. These repurchased shares will be canceled, reducing the company’s registered capital and shareholding structure.

Concurrently, Livzon Pharmaceutical's subsidiary, Livzon MAb, received acceptance from the National Medical Products Administration for its innovative drug, Leiqikita Monoclonal Antibody Injection (160mg/1.6mL). This drug, a self-developed IL-17A/F dual-target inhibitor, is designed to treat moderate to severe plaque psoriasis. Total R&D investment for the drug was approximately RMB 204,030,000.

The drug’s market entry is significant as there are currently no other IL-17A/F dual-target products approved for psoriasis in China. The company will proceed with the registration and approval process.